Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Lyell Immunopharma (LYEL) reported an insider transaction by its President and CEO, who is also a Director. On 11/10/2025, the insider sold 412 shares of common stock at $16.11 per share. The filing states these shares were automatically sold to cover tax withholding from the settlement of vested restricted stock units. Following the transaction, the insider beneficially owns 67,159 shares, held directly.
Lyell Immunopharma (LYEL) reported an insider transaction by its VP, Corporate Controller. On 11/10/2025, the officer sold 239 shares of common stock at a weighted average price of $16.10.
The filing states the shares were automatically sold to cover tax withholding from the settlement of vested RSUs. Following the transaction, the officer beneficially owns 9,213 shares, held directly.
Lyell Immunopharma (LYEL) reported an insider transaction by its Chief Operating Officer on a Form 4. The filing shows an automatic sale of 95 shares of common stock at $16.12 on 11/10/2025 to satisfy tax withholding from the settlement of vested restricted stock units.
Following this tax-related sale, the reporting person directly holds 15,750 shares of Lyell common stock.
Lyell Immunopharma (LYEL) reported Q3 2025 results highlighted by continued R&D investment, a narrowed quarterly loss, and a mid‑year capital raise. The company recorded revenue of $15 thousand and a net loss of $38.8 million, improving from a $44.6 million loss a year ago. Operating expenses were $37.3 million, with research and development at $28.2 million and general and administrative at $10.7 million. Interest income contributed $3.3 million. Year‑to‑date, net loss was $133.7 million.
Liquidity remained strong. Cash and cash equivalents were $123.6 million and marketable securities were $196.0 million as of September 30, 2025, for total current liquid investments of $319.6 million. Net cash used in operating activities was $117.8 million for the nine months. In July, the company raised $50.0 million by issuing 3,753,752 shares at $13.32 per share under a Securities Purchase Agreement and recognized a related SPA put/call asset. A 1‑for‑20 reverse stock split was effected on May 30, 2025. Shares outstanding were 19,294, as of quarter‑end, and 21,218,217 as of November 10, 2025.
The company issued 625,000 shares valued at $5.9 million upon achieving an ImmPACT milestone. It also recorded a $1.4 million impairment tied to closing its West Hills facility after transitioning manufacturing to its LyFE center in Bothell, WA.
Lyell Immunopharma, Inc. furnished an update on its financial results for the quarter ended September 30, 2025 via a Form 8‑K. The company attached a press release as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, and is therefore not subject to Section 18 liabilities and is not incorporated by reference except as specifically stated.
Lyell Immunopharma (LYEL) filed an initial statement of beneficial ownership for its VP, Corporate Controller, effective 10/31/2025. The reporting person holds 9,452 shares of common stock directly, which includes RSUs subject to time-based vesting beginning after August 9, 2025. They also hold stock options to purchase 1,674, 624, and 3,000 shares at exercise prices of $42.6 and $37.4, expiring on 02/23/2033, 03/15/2032, and 09/09/2031, respectively, with noted vesting schedules.
Lyell Immunopharma (LYEL) signed an Exclusive License Agreement with Innovative Cellular Therapeutics, gaining rights to research, develop, manufacture and commercialize certain cell therapy candidates worldwide except mainland China, Taiwan, Macau and Hong Kong. In return, Lyell will pay $40 million in cash and issue 1.9 million common shares to ICT Holdings.
The deal includes meaningful performance-based economics: a potential $30 million clinical milestone, up to $115 million in late-stage regulatory milestones, and up to $675 million in commercial sales milestones, plus up to an additional 1.85 million shares upon certain clinical and regulatory milestones. Tiered royalties apply, ranging from mid-single digits up to 10% on U.S. net sales and low to mid-single digits elsewhere in the licensed territory.
Lyell also entered a Registration Rights Agreement to provide ICT Holdings with shelf registration for the resale of shares issuable under the license. The securities were issued in a private placement in reliance on Section 4(a)(2) of the Securities Act.
Lyell Immunopharma (LYEL) announced leadership changes in its finance function. On October 31, 2025, the Board appointed CEO Lynn Seely, M.D., as interim principal financial officer and named Veronica Sanchez Bulis as principal accounting officer.
Bulis has served as Vice President, Corporate Controller since August 2021 and previously held senior finance roles at Sangamo Therapeutics (2018–2021) and Core-Mark International (2008–2018), with earlier public accounting experience at Ernst & Young and Deloitte.
Lyell Immunopharma (LYEL) reported insider activity by its Chief Operating Officer via Form 4. On 10/27/2025, the officer received an option to buy 75,000 shares of common stock at an exercise price of $17.23. The award vests with 12.5% of the option shares on April 27, 2026, and the remainder in equal monthly installments over the following 42 months, subject to continued service. Following the reported transactions, the officer beneficially owned 15,845 shares of common stock, held directly.
Lyell Immunopharma (LYEL) reported an insider equity award. The company’s Chief Scientific Officer filed a Form 4 showing an option grant for 68,000 shares with an exercise price of $17.23 on 10/27/2025. These options expire on 10/26/2035.
Vesting is staged: 12.5% vests on 4/27/2026, with the remainder vesting in equal monthly installments over the following 42 months, contingent on continued service. Following the reported transactions, the insider reported 15,504 shares of common stock beneficially owned, held directly.